Valuation: Cerenome, Inc.

Market Cap 5.08M 4.53M 4.14M 3.77M 7.11M 480M 7.31M 49.78M 19.91M 254M 19.08M 18.67M 803M P/E 2026 *
-0.14x
P/E 2027 * -0.27x
Enterprise Value 5.08M 4.53M 4.14M 3.77M 7.11M 480M 7.31M 49.78M 19.91M 254M 19.08M 18.67M 803M EV / Sales 2026 *
1.37x
EV / Sales 2027 * 0.27x
Free-Float
97.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Cerenome, Inc.

1 day-24.87%
1 week-61.50%
Current month-60.59%
1 month-57.06%
3 months-82.87%
6 months-89.23%
Current year-94.77%
1 week 0.63
Extreme 0.63
4.25
1 month 0.63
Extreme 0.63
4.25
Current year 0.63
Extreme 0.63
15.32
1 year 0.63
Extreme 0.63
18.88
3 years 0.63
Extreme 0.63
69.5
5 years 0.63
Extreme 0.63
810
10 years 0.63
Extreme 0.63
399,377.5
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 A Exercice

Director

1,842 0.0268%
10/1/26 A Exercice

Director

1,842 0.0268%
10/1/26 A Exercice

Chairman

1,842 0.0268%
Change 5-day change 1-year change 3-year change Capi.($)
-24.87%-61.50%-95.08%-98.33% 6.77M
+3.80%+8.10%+63.78%+77.70% 66.87B
+0.07%+1.39%+12.75%+75.17% 57.2B
+1.63%+4.93%+24.89%+104.31% 56.55B
+0.41%-3.70%+26.06%+34.32% 43.47B
+2.51%+4.22%+20.49%+110.71% 42.95B
-11.04%-6.63%+199.38%+701.67% 42.8B
+7.50%+13.58%+29.07%+64.46% 34.01B
+1.59%-4.04%+97.66%+79.95% 32.11B
-2.75%+6.38%+35.20%-5.55% 25.27B
Average -2.12%-2.12%+41.42%+114.44% 40.12B
Weighted average by Cap. +0.60%+3.42%+54.73%+140.30%

Financials

2026 *2027 *
Net sales 3.72M 3.31M 3.03M 2.76M 5.2M 351M 5.34M 36.42M 14.56M 186M 13.96M 13.66M 587M 19.14M 17.06M 15.6M 14.21M 26.78M 1.81B 27.5M 187M 74.95M 958M 71.85M 70.3M 3.02B
Net income -32.63M -29.08M -26.6M -24.22M -45.66M -3.08B -46.89M -320M -128M -1.63B -122M -120M -5.15B -19.05M -16.98M -15.53M -14.14M -26.66M -1.8B -27.38M -187M -74.61M -954M -71.52M -69.99M -3.01B
Net Debt - -
Projected Income Statement - Annual - Cerenome, Inc.
Logo Cerenome, Inc.
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
Employees
28
Date Price Change Volume
05/11/26 $0.6699 -24.87% 1,155,072
04/11/26 $0.8916 -31.42% 2,457,351
03/11/26 $1.300 -23.98% 29,020,882
02/11/26 $1.710 +0.59% 51,951
30/10/26 $1.700 -2.30% 47,772
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cerenome, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.6699USD
Average target price
27.75USD
Spread / Average Target
+4,042.41%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerenome, Inc.
  1. Stock Market
  2. Stocks
  3. CNSY Stock